<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01283776</url>
  </required_header>
  <id_info>
    <org_study_id>Uni-Koeln-1430</org_study_id>
    <nct_id>NCT01283776</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation</brief_title>
  <acronym>OCTET-CY</acronym>
  <official_title>A Phase II Study to Investigate the Efficacy of Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II clinical study to assess the efficacy of post-transplantation cyclophosphamide as
      single-agent GvHD prophylaxis after allogeneic hematopoietic stem cell transplantation in
      patients with multiple myeloma or lymphoma and to describe the influence of the modified
      immunosuppression concept on relapse rates, minimal residual disease, immune reconstitution
      and chimerism.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients not requiring additional immunosuppression</measure>
    <time_frame>day 100 after transplant</time_frame>
    <description>The primary endpoint is met if at least 1 of the 5 first patients and 3 of a total of 11 patient will reach day 100 after transplant without additional immunsuppressive drug treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>day 100 after transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>engraftment</measure>
    <time_frame>day 100 after transplant</time_frame>
    <description>absolute neutrophil count of &gt; 0.5 x 10e9/l on 3 consecutive days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chimerism</measure>
    <time_frame>day 100 after transplant</time_frame>
    <description>Percentage of donor cells in leukocytes from peripheral blood or bone marrow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse incidence</measure>
    <time_frame>day 100 after transplant</time_frame>
    <description>cumulative incidence of relapse until day 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute GvHD</measure>
    <time_frame>day 100 after transplant</time_frame>
    <description>cumulative incidence of acute GvHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-relapse mortality</measure>
    <time_frame>day 100 after transplant</time_frame>
    <description>cumulative incidence of death from any cause without prior relapse or progression of malignant disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immune reconstitution</measure>
    <time_frame>day 100 after transplant</time_frame>
    <description>relative and absolute counts of B- and T-lymphocyte subsets in peripheral blood</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Non-Hodgkin-Lymphoma</condition>
  <condition>Hodgkin's Disease</condition>
  <arm_group>
    <arm_group_label>treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclophosphamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>100 mg/kg total dose, infused on day +3 and +3 after allogeneic stem cell transplantation</description>
    <arm_group_label>treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with multiple myeloma, Non-Hodgkin's lymphoma or Hodgkin's disease after
             allogeneic stem cell transplantation with reduced intensity conditioning

               -  Written informed consent

               -  No uncontrolled infections

        Exclusion Criteria:

          -  Severe organ dysfunction defined as:

          -  Cardiac left ventricular ejection fraction (LVEF) of less than 35%

          -  diffusing lung capacity (DLCO) of less than 40%

          -  total lung capacity (TLC) of less than 40%

          -  forced expiratory volume (FEV1) of less than 40%

          -  total bilirubin &gt;3mg/dl

          -  creatinine-clearance of less than 40 ml/min

          -  pregnancy or breast feeding

          -  participation in other experimental drug trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Scheid, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cologne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2011</study_first_submitted>
  <study_first_submitted_qc>January 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2011</study_first_posted>
  <last_update_submitted>June 8, 2014</last_update_submitted>
  <last_update_submitted_qc>June 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Christoph Scheid</investigator_full_name>
    <investigator_title>PD Dr. Christoph Scheid</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

